RESULTS FOR : 'Phenotypic'
Showing 1 to 12 of 12 results |    
Keyword Search
Results Category/Section
High-Content and Phenotypic Screening 2020

Dates: 25-26 March 2020 Venue: Boston, USA

Optimising Phenotypic Screening - Single-cell analysis versus 3D multicell analysis

In light of the high failure rate of compounds when they are subjected to clinical testing, we are seeing a renaissance in phenotypic screening in drug discovery. However, most phenotypic screening is based on the use of cellular assays and here we debate the advantages and disadvantages of single-cell versus 3D multi-cell analyses.

Fail Early, Fail Fast - A phenotypic rescue approach

New disease targets frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery programme is often lacking.

How Phenotypic CRISPR Screening is Revolutionising Drug Discovery

Research in drug discovery and biotechnology increasingly exploits gene editing at industrial scale in order to identify and validate new biological targets for precision medicines. The discovery of CRISPR-Cas9 systems has fuelled a rapid expansion of gene editing adoption with particular interest in the increasingly prevalent area of functional genomic screening.

Phenotypic Drug Discovery With High Content Screening

Early drug discovery used to be conducted mainly in a target-agnostic fashion, focusing on qualitative readouts from a living system - cells, tissue, or organisms - and asking the question, did this entity affect the phenotype?

Novel Drug Targets From Phenotypic Screening

Identifying functional molecules with the potential to be developed into new therapeutics is often the sole aim of phenotypic drug discovery. However, the approach also provides valuable opportunities to uncover previously unknown, disease-specific drug receptors that can then be exploited through target driven means.

Phenotypic Screening - Advancing the science from discovery to regulatory science

Phenotypic screening is transforming drug discovery as advances are made in development of human-based physiologically-relevant in vitro systems.

Phenotypic Drug Discovery: Striving towards the highest level of biological relevance

Phenotypic drug discovery (PDD) implies screening where the molecular mechanism of action is not assumed and does not require knowledge of the molecular target.

High Throughput Flow: A High Content Platform For Phenotypic Screening?

Flow cytometry has many of the technology attributes (eg multi-parameter analysis of cell suspensions) needed when attempting to profile a phenotypic drug response. However, for flow cytometry to be considered the phenotypic drug screening platform of choice it needs to interface with the real screening world, ie be able to support higher throughput and to acquire low sample volumes from high density microplates.

Opportunities For Phenotypic Screening In Drug Discovery

Renewed awareness of the value of phenotypic screening to drug discovery creates many new opportunities to increase drug discovery success and productivity.

Systems Biology - Precise phenotypic anchoring for drug target identification, validation and biomarker discovery

The pharmaceutical industry has not seen the hoped-for productivity gains from the various omics datastreams over the last decade. This article discusses how systems biology can exploit the natural interlinkages between these datastreams and put in place a powerful system for modern therapeutic development.